Sanofi gets global rights to Revolution's SHP2 inhibitors; Deal terminated
Sanofi partnered with Revolution Medicines Inc. to develop and sell small-molecule SHP2 inhibitors for cancer.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.